Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 22, Kristen Kluska from Cantor Fitzgerald reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $105.00. Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported$ 166 million in total revenue for fiscal Q2 2025, with Crysvita revenue comin ...